Dose escalation with proton-beam boost for low-risk prostate cancer

被引：2
作者：
Trabulsi, E. J.
Valicenti, R. K. [1 ]
机构：
[1] Thomas Jefferson Univ, Dept Radiat Oncol, Clin Div, Philadelphia, PA 19107 USA
[2] Thomas Jefferson Univ, Dept Urol, Philadelphia, PA 19107 USA
来源：
NATURE CLINICAL PRACTICE UROLOGY | 2006年 / 3卷 / 05期
关键词：
biochemical failure; conformal radiotherapy; dose; morbidity; prostate cancer;
D O I：
10.1038/ncpuro0477
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：256 / 257
页数：2
相关论文
共 50 条
  • [41] A prospective dose escalation trial of high-dose-rate brachytherapy boost for prostate cancer: Evidence of hypofractionation efficacy?
    Tang, Johann I.
    Williams, Scott G.
    Tai, Keen Hun
    Dean, Joanne
    Duchesne, Gillian M.
    BRACHYTHERAPY, 2006, 5 (04) : 256 - 261
  • [42] DOSE ESCALATION IN THE RADIATION THERAPY OF PROSTATE CANCER
    Schulz, Robert J.
    Kagan, A. Robert
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2011, 80 (05): : 1289 - 1291
  • [43] Hazards of dose escalation in prostate cancer radiotherapy
    Kuban, D
    Pollack, A
    Huang, E
    Levy, L
    Dong, L
    Starkschall, G
    Rosen, I
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2003, 57 (05): : 1260 - 1268
  • [44] Morbidity and prostate-specific antigen control of external beam radiation therapy plus low-dose-rate brachytherapy boost for low, intermediate, and high-risk prostate cancer
    Koontz, Bridget F.
    Chino, Junzo
    Lee, W. Robert
    Hahn, Carol A.
    Buckley, Niall
    Huang, Samuel
    Kim, Jay
    Reagan, Robert
    Joyner, Raymond
    Anscher, Mitchell S.
    BRACHYTHERAPY, 2009, 8 (02) : 191 - 196
  • [45] The effect of dose-escalation radiotherapy with simultaneous-integrated-boost on the use of short-term androgen deprivation therapy in patients with intermediate risk prostate cancer
    Onal, Cem
    Guler, Ozan Cem
    Erbay, Gurcan
    Elmali, Aysenur
    PROSTATE, 2024, 84 (08) : 763 - 771
  • [46] Focal Cryotherapy in Low-Risk Prostate Cancer: Are We Treating the Cancer or the Mind? The Cancer
    da Silva, Rodrigo Donalisio
    Kim, Fernando J.
    INTERNATIONAL BRAZ J UROL, 2015, 41 (01): : 5 - 9
  • [47] A randomized controlled trial evaluating the effect of low-dose chlormadinone in patients with low-risk prostate cancer: PROSAS study
    Sugimoto, Mikio
    Kakehi, Yoshiyuki
    Horie, Shigeo
    Hirao, Yoshihiko
    Akaza, Hideyuki
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2022, 52 (02) : 187 - 196
  • [48] Variations in patterns of concurrent androgen deprivation therapy use based on dose escalation with external beam radiotherapy vs. brachytherapy boost for prostate cancer
    Mohiuddin, Jahan J.
    Narayan, Vivek
    Venigalla, Sriram
    Vapiwala, Neha
    BRACHYTHERAPY, 2019, 18 (03) : 322 - 331
  • [49] Can we avoid dose escalation for intermediate-risk prostate cancer in the setting of short-course neoadjuvant androgen deprivation?
    Shakespeare, Thomas P.
    Wilcox, Shea W.
    Aherne, Noel J.
    ONCOTARGETS AND THERAPY, 2016, 9 : 1635 - 1639
  • [50] Active Surveillance for Low-risk Prostate Cancer: Are All Criteria Similar?
    Cimino, Sebastiano
    Privitera, Salvatore
    Favilla, Vincenzo
    Cantiello, Francesco
    Manno, Stefano
    Cicione, Antonio
    Damiano, Rocco
    Russo, Giorgio Ivan
    Morgia, Giuseppe
    ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY, 2018, 18 (07) : 958 - 963
12345